Skip to main content
. 2017 Jul 10;2017:1315432. doi: 10.1155/2017/1315432

Table 4.

Analysis of adverse events observed in patients in the treatment groups (n  (%)).

Event JieDuTongLuoShengJin granules + HCQ (%) Placebo + HCQ (%)
Week 4
 Erythra 1 (5.0) 0 (0.0)
Week 12
 Liver dysfunction 0 (0.0) 1 (5.0)
 Erythra 1 (5.0) 1 (5.0)
 Pancreatitis 0 (0.0) 1 (5.0)